Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...

French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition.

IonQ shares traded higher Monday after the company announced results of a collaborative research program with AstraZeneca, ...

The astraszenecaglobal.xyz scam is abusing the real pharmaceutical giant’s name to run a fake investment scheme targeting ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

IonQ (IONQ) announced results of a research program between the company, AstraZeneca (AZN), Amazon Web Services (AMZN) and Nvidia (NVDA).

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Comparative assessments and other editorial opinions are those of U.S. News and have not been previously reviewed, approved ...